45.76
-1.75 (-3.68%)
| Previous Close | 47.51 |
| Volume | 267,532 |
| Price / Earnings (Forward) | 19.64 |
| Price / Sales | 5.78 |
| Price / Book | 133.52 |
| 52 Weeks Range |
| Profit Margin | -125.70% |
| Operating Margin (TTM) | -99.16% |
| Diluted EPS (TTM) | -4.76 |
| Quarterly Revenue Growth (YOY) | 286.80% |
| Total Debt/Equity (MRQ) | 1,016.89% |
| Current Ratio (MRQ) | 8.25 |
| Operating Cash Flow (TTM) | -108.78 M |
| Levered Free Cash Flow (TTM) | -60.04 M |
| Return on Assets (TTM) | -15.14% |
| Return on Equity (TTM) | -343.83% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | AnaptysBio, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 2.1 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | -5.0 |
| Relative Valuation | NA |
| Financial Health | -2.5 |
| Macro Environment | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | -1.26 |
Select this tab to load the latest available analysis.
|
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 5.09% |
| % Held by Institutions | 133.99% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Ecor1 Capital, Llc | 30 Jun 2026 | 7,880,094 |
| Tang Capital Management Llc | 30 Jun 2026 | 1,330,879 |
| Affinity Asset Advisors, Llc | 30 Jun 2026 | 826,109 |
| Woodline Partners Lp | 30 Jun 2026 | 717,014 |
| 683 Capital Management, Llc | 30 Jun 2026 | 660,000 |
| Palo Alto Investors Lp | 30 Jun 2026 | 603,489 |
| First Light Asset Management, Llc | 30 Jun 2026 | 582,004 |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |